Feedback 中 文 | english

Message Board

About us
Company Overview

Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese  medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.


In April 2016, the company was founded by three co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.


The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 39.07 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT an innovative technology enterprise in the radiopharmaceutical industry in China.


By March 2019, CNRT has completed the phase one construction of the of the pilot plant, testing center, and labelling workshop for radioactive drugs, and the animal laboratory. The company was awarded the "Top 12 of 6th Chinese Innovation and Entrepreneurship Competition of Biological Medicine Industry" and "Grand Prize of Sichuan Provincial Innovation and Entrepreneurship Competition".


In October 2018, CNRT obtained the “Radiation Safety Licence” issued by the Ministry of Ecology and Environment (includes 1 class A site, 2 class B sites, and 1 class C site). In January 2019, the company acquired the “License for the Use of Experimental Animals” issued by Sichuan Provincial Commission of Experimental Animals.


The series accomplishment listed above has granted sufficient support for the scientific research and manufacturing projects. On the other hand, this provide a brand new platform for Chinese radiopharmaceutical development and clinical application.


With the respect of life and health, CNRT will devote our efforts to research and develop the application of nuclear technology. With international cooperation, top tier R&D team and innovative platform, and standardized quality control system, CNRT will ensure the continuously supply of high quality drugs with reasonable price for patients worldwide. 




Organizational Chart
Corporate honor
成都纽瑞特医疗科技股份有限公司| 蜀ICP备19000821号 ©Copyright 2018 All Right Reserved.